To access this element change to forms mode OFF
Grant Award View - GA89312
AZA+: A multi-site phase 1/2 dose escalation/expansion trial combining...
GA ID:
GA89312
Agency:
Department of Health and Aged Care
Approval Date:
25-May-2020
Publish Date:
29-Jun-2020
Category:
Health and Medical Research
Grant Term:
1-Jun-2020 to 31-May-2025
Value (AUD):
$3,328,735.50
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 19/20 1.1 Health Policy Research and Analysis
Grant Program:
2019_MRFF_RCRDUN_RCRDUN_2020
Grant Activity:
AZA+: A multi-site phase 1/2 dose escalation/expansion trial combining azacitidine and defactinib for high-risk myelodysplastic syndrome patients who fail to respond to azacitidine alone
Purpose:
High-risk Myelodysplasia (HR-MDS) is a rare form of blood cancer that results in failure of normal blood cell production and acute leukemia. The only registered drug (AZA) works in only half of patients and non-responders have an extremely poor prognosis. AZA non-responder HR MDS patients have an unmet need for new therapies. We have identified a drug (defactinib) that improves AZA response in MDS. We will HR-MDS patients to evaluate safety and efficacy of this combination.
GO ID:
GO Title:
MRFF Clinical Trials Activity - RCRDUN Initiative – 2019 Rare Cancers, Rare Diseases and Unmet Need Grant Opportunity
Internal Reference ID:
MRF1200271
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Sydney
Town/City:
Sydney
Postcode:
2052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, SA, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, UNITED KINGDOM, UNITED STATES